MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Vivani Medical

Suletud

1 -4.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.99

Max

1.03

Põhinäitajad

By Trading Economics

Töötajad

36

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+471.43% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

9. mai 2025

Turustatistika

By TradingEconomics

Turukapital

61M

Eelmine avamishind

5.76

Eelmine sulgemishind

1

Vivani Medical Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. juuni 2024, 15:28 UTC

Suurimad hinnamuutused turgudel

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Võrdlus sarnastega

Hinnamuutus

Vivani Medical Prognoos

Hinnasiht

By TipRanks

471.43% tõus

12 kuu keskmine prognoos

Keskmine 6 USD  471.43%

Kõrge 8 USD

Madal 4 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Vivani Medical 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Finantsandmed

$

Ettevõttest Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.